ALL study

The ALL project: over 50,000 people surveyed in 20 countries on 5 continents.

On the occasion of the 25th World Congress of Dermatology (WCD), held in Singapore from July 4 to 7, 2023, the Pierre Fabre Patient-Consumer Relations Department presented the ALL project, a large-scale survey, the largest ever carried out in dermatology.

Launched at the end of 2022 with the help of EMMA, the project aims to collect data on all skin types (ALL Skins), all skin diseases (ALL Dermatoses) and all phototypes (ALL Colors) , making itthe largest international private database in dermo-cosmetics.

The survey questionnaire, designed in partnership with dermatology specialists and patient associations, covers some 20 dermatological therapeutic areas. 50,552 people from adult populations in 20 countries (representing over 50% of the world's population) on 5 continents answered the 65 questions in the ALL project.

The main themes addressed are related to the prevalence and impact of pathologies, but also to the behaviours, care pathways and needs of patients affected by one or more dermatoses such as atopic dermatitis, psoriasis, acne, rosacea or vitiligo (see exhaustive list of topics in Appendix 1).

The strength of this study lies in the considerable scope of the data collected, and their representativeness: respondents were drawn from samples proportional to the population of each country (sample sizes by country in Appendix 2), enabling a highly reliable analysis of needs on a global scale, by geographical territory.

ALL data was collected in June 2023, and will continue to be extracted over the next 5 years (2023-2027). The 3.3 million pieces of data will enable us to identify the information essential to a better understanding of patients' experiences.

The creation of this database, exceptional in its geographical coverage, confirms our commitment to working alongside healthcare professionals worldwide to help improve the quality of life of patients suffering from skin disorders. A better understanding of their expectations will enable us to orientate our work and innovate in order to better support them in their dermatological care.

Núria PEREZ CULLEL

Medical Director, Patient/Consumer Relations Pierre Fabre

More than one in three people ( 41%) surveyed said they had suffered from a skin disease in the last 12 months, yet health and prevention policies do not consider dermatology to be a public health priority. The ALL study aims to provide a global overview of the prevalence of major skin diseases and their consequences, in order to generate awareness among all stakeholders. Patients suffering from dermatological diseases need more support, and it is essential to succeed in convincing public authorities to attach greater importance to dermatoses in prevention programs.

This work, the only one of its kind, has already won the support of internationally renowned opinion leaders: Professor Jean Hilaire SAURAT from the University of Geneva for acne, Professor Gil YOSIPOVITCH from the University of Miami, for pruritus, Professors Henry LIM from the University of Detroit and Khaled EZZEDINE, dermatologist at APH Paris, for photoprotection, Professor Julien SENESCHAL, dermatologist at Bordeaux University Hospital for vitiligo and Professor Marie Aleth RICHARD, dermatologist at APH Marseille and former president of the SFD.Ramon GRIMALT, Professor of Dermatology at the International University of Catalonia, for seborrheic dermatitis.

Data from the ALL study are shared with patient associations to help them make their case to the general public, healthcare professionals and the authorities. 12 patient associations have already been involved in this process in France and abroad.

The results are the subject of scientific communications (22 posters and 6 publications: 1 in the JAAD; 4 in the JEADV; 1 BJD ) which contribute to a better understanding and recognition of skin diseases.

To find out more about the ALL Study , visit theChanger de regard website for press releases, posters, publications, videos and other publications .

For healthcare professionals, the ALL project is unique. Thanks to its methodology, it will enable us to describe for the first time the perceived prevalence of pruritus throughout the world, regardless of patients' ethnicity, sex, age or region!

Professor Gil YOSIPOVITCH MD

Director of the Miami Itch Center (Dr. Phillip Frost Dept. of Dermatology, Miller School of Medicine, Miami USA).

Appendices

Appendix 1: List of subjects studied

Acne, psoriasis, rosacea, eczema, lentigo, skin cancers, vitiligo, hair and nail disorders, wounds/healing, pain and pruritus, cosmetic procedures, sun protection.

Appendix 2: Sample sizes by country

5000 people in China; 5000 people in the USA; 4001 people in Brazil; 4001 people in Italy; 4000 people in France; 4000 people in Germany; 4000 people in Spain; 3000 people in India; 2500 people in Canada; 2500 people in Mexico; 2500 people in Poland; 2500 people in South Korea; 2000 people in Australia; 1000 people in Denmark; 1000 people in Israel; 1000 people in Portugal; 1000 people in South Africa; 750 people in the United Arab Emirates; 500 people in Kenya; 300 people in Senegal.